Amivantamab and Lazertinib in Patients with EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum

Поділитися
Вставка
  • Опубліковано 16 вер 2024

КОМЕНТАРІ • 3

  • @binebum1
    @binebum1 Рік тому

    Excellent very clear thank you

  • @corgis7083
    @corgis7083 3 місяці тому

    Common names also in studies would help with communication with patience.

    • @CancergraceOrg
      @CancergraceOrg  3 місяці тому

      Yes, I agree. We encourage our faculty to use both generic and brand names which is a pretty easy thing to miss in a live webinar for our faculty who are accustom to using just one term. I'll pass your note along to our program manager and she may be able to correct this type of oversight in edit. Thanks for the input.